Abstract
Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Keywords: Blood pressure, diabetes mellitus, renin-angiotensin-system, diabetic retinopathy, DIRECT, NAVIGATOR, DREAM, EUCLID
Current Pharmaceutical Biotechnology
Title: The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Volume: 12 Issue: 3
Author(s): V. Swetha E. Jeganathan
Affiliation:
Keywords: Blood pressure, diabetes mellitus, renin-angiotensin-system, diabetic retinopathy, DIRECT, NAVIGATOR, DREAM, EUCLID
Abstract: Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Export Options
About this article
Cite this article as:
Swetha E. Jeganathan V., The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy, Current Pharmaceutical Biotechnology 2011; 12 (3) . https://dx.doi.org/10.2174/138920111794480615
DOI https://dx.doi.org/10.2174/138920111794480615 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunosuppression in Liver Transplantation
Current Drug Targets Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Decorin Biology, Expression, Function and Therapy in the Cornea
Current Molecular Medicine Epigenetic Mechanisms and Kidney Diseases
Current Medicinal Chemistry Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Mimicking Microvascular Alterations of Human Diabetic Retinopathy: A Challenge for the Mouse Models
Current Medicinal Chemistry New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Ultrasound Therapeutics– A Review
Current Medical Imaging Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry A New Biomarker with High Outcome Prediction in IgA Nephropathy
Recent Patents on Biomarkers Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology Editorial [Hot Topic: New Concepts of Angiotensin Receptor Blocker (ARB) in Atherosclerosis: ARB as a Metabolic-Improving Agent (Guest Editor: Minako Yamaoka-Tojo)]
Current Vascular Pharmacology Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes
Current Medicinal Chemistry Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry